QuidelOrtho (QDEL)
Market Price (12/29/2025): $29.29 | Market Cap: $2.0 BilSector: Health Care | Industry: Health Care Supplies
QuidelOrtho (QDEL)
Market Price (12/29/2025): $29.29Market Cap: $2.0 BilSector: Health CareIndustry: Health Care Supplies
Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.
| Megatrend and thematic driversMegatrends include Biotechnology & Genomics, Precision Medicine, and Aging Population & Chronic Disease. Themes include Advanced Diagnostics, Show more. | Weak multi-year price returns2Y Excs Rtn is -106%, 3Y Excs Rtn is -145% | Debt is significantNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is 138% |
| Meaningful short interestShort Interest Days-to-CoverDTC = (Short Interest Share Quantity) / (Average Daily Trading Volume). Reflects how many days it would take to cover (close out) the short interest based on average volumes. High DTC can signify an increased risk of a short squeeze. is 12.1, Short Interest % of Basic SharesShort Interest % of Basic Shares = (Short Interest Quantity) / (Basic Shares Outstanding). A high fraction of short interest can indicate potential risk of a short squeeze. is 17% | Expensive valuation multiplesP/CFOPrice/(Cash Flow from Operations). CFO is cash before capital expenditures. is 54x | |
| Weak revenue growthRev Chg LTMRevenue Change % Last Twelve Months (LTM) is -3.7%, Rev Chg 3Y AvgRevenue Change % averaged over trailing 3 years is -3.5%, Rev Chg QQuarterly Revenue Change % is -3.7% | ||
| Not cash flow generativeFCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -5.6% | ||
| Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -63% | ||
| Key risksQDEL key risks include [1] significant revenue pressure from declining COVID-19 testing demand and product development failures, Show more. |
| Megatrend and thematic driversMegatrends include Biotechnology & Genomics, Precision Medicine, and Aging Population & Chronic Disease. Themes include Advanced Diagnostics, Show more. |
| Weak multi-year price returns2Y Excs Rtn is -106%, 3Y Excs Rtn is -145% |
| Meaningful short interestShort Interest Days-to-CoverDTC = (Short Interest Share Quantity) / (Average Daily Trading Volume). Reflects how many days it would take to cover (close out) the short interest based on average volumes. High DTC can signify an increased risk of a short squeeze. is 12.1, Short Interest % of Basic SharesShort Interest % of Basic Shares = (Short Interest Quantity) / (Basic Shares Outstanding). A high fraction of short interest can indicate potential risk of a short squeeze. is 17% |
| Debt is significantNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is 138% |
| Expensive valuation multiplesP/CFOPrice/(Cash Flow from Operations). CFO is cash before capital expenditures. is 54x |
| Weak revenue growthRev Chg LTMRevenue Change % Last Twelve Months (LTM) is -3.7%, Rev Chg 3Y AvgRevenue Change % averaged over trailing 3 years is -3.5%, Rev Chg QQuarterly Revenue Change % is -3.7% |
| Not cash flow generativeFCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -5.6% |
| Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -63% |
| Key risksQDEL key risks include [1] significant revenue pressure from declining COVID-19 testing demand and product development failures, Show more. |
Why The Stock Moved
Qualitative Assessment
AI Analysis | Feedback
Here are key points highlighting potential reasons for QuidelOrtho's (QDEL) stock movement during the approximate period from August 31, 2025, to December 29, 2025:
1. FDA 510(k) Clearance for VITROS™ Immunodiagnostic Products hs Troponin I Assay.
On November 3, 2025, QuidelOrtho received FDA 510(k) clearance for its VITROS™ Immunodiagnostic Products hs Troponin I Assay. This approval expanded the company's portfolio in in vitro diagnostics, specifically for high-sensitivity Troponin I assays, which provide crucial diagnostic insights for patient care. Following this announcement, the stock price moved from $26.99 on October 31, 2025, to $27.71 on November 3, 2025, marking an approximate 2.67% increase.
2. Third Quarter 2025 Financial Results.
QuidelOrtho announced its third quarter 2025 financial results on November 5, 2025. The company reported total revenue of $700 million and an adjusted diluted EPS of $0.80. Despite a GAAP net loss that included a significant goodwill impairment charge, the adjusted EBITDA margin improved by 180 basis points to 25%, driven by cost-savings initiatives. These results could have influenced investor sentiment.
Show more
1. FDA 510(k) Clearance for VITROS™ Immunodiagnostic Products hs Troponin I Assay.
On November 3, 2025, QuidelOrtho received FDA 510(k) clearance for its VITROS™ Immunodiagnostic Products hs Troponin I Assay. This approval expanded the company's portfolio in in vitro diagnostics, specifically for high-sensitivity Troponin I assays, which provide crucial diagnostic insights for patient care. Following this announcement, the stock price moved from $26.99 on October 31, 2025, to $27.71 on November 3, 2025, marking an approximate 2.67% increase.
2. Third Quarter 2025 Financial Results.
QuidelOrtho announced its third quarter 2025 financial results on November 5, 2025. The company reported total revenue of $700 million and an adjusted diluted EPS of $0.80. Despite a GAAP net loss that included a significant goodwill impairment charge, the adjusted EBITDA margin improved by 180 basis points to 25%, driven by cost-savings initiatives. These results could have influenced investor sentiment.
Show more
Stock Movement Drivers
Fundamental Drivers
The 3.4% change in QDEL stock from 9/28/2025 to 12/28/2025 was primarily driven by a 4.9% change in the company's P/S Multiple.| 9282025 | 12282025 | Change | |
|---|---|---|---|
| Stock Price ($) | 28.33 | 29.30 | 3.42% |
| Change Contribution By | LTM | LTM | |
| Total Revenues ($ Mil) | 2741.60 | 2714.40 | -0.99% |
| P/S Multiple | 0.70 | 0.73 | 4.92% |
| Shares Outstanding (Mil) | 67.70 | 68.00 | -0.44% |
| Cumulative Contribution | 3.42% |
Market Drivers
9/28/2025 to 12/28/2025| Return | Correlation | |
|---|---|---|
| QDEL | 3.4% | |
| Market (SPY) | 4.3% | 37.7% |
| Sector (XLV) | 15.2% | 44.9% |
Fundamental Drivers
The 1.5% change in QDEL stock from 6/29/2025 to 12/28/2025 was primarily driven by a 4.1% change in the company's P/S Multiple.| 6292025 | 12282025 | Change | |
|---|---|---|---|
| Stock Price ($) | 28.87 | 29.30 | 1.49% |
| Change Contribution By | LTM | LTM | |
| Total Revenues ($ Mil) | 2764.70 | 2714.40 | -1.82% |
| P/S Multiple | 0.70 | 0.73 | 4.14% |
| Shares Outstanding (Mil) | 67.50 | 68.00 | -0.74% |
| Cumulative Contribution | 1.48% |
Market Drivers
6/29/2025 to 12/28/2025| Return | Correlation | |
|---|---|---|
| QDEL | 1.5% | |
| Market (SPY) | 12.6% | 40.7% |
| Sector (XLV) | 17.0% | 49.8% |
Fundamental Drivers
The -33.8% change in QDEL stock from 12/28/2024 to 12/28/2025 was primarily driven by a -30.6% change in the company's P/S Multiple.| 12282024 | 12282025 | Change | |
|---|---|---|---|
| Stock Price ($) | 44.25 | 29.30 | -33.79% |
| Change Contribution By | LTM | LTM | |
| Total Revenues ($ Mil) | 2817.70 | 2714.40 | -3.67% |
| P/S Multiple | 1.06 | 0.73 | -30.55% |
| Shares Outstanding (Mil) | 67.30 | 68.00 | -1.04% |
| Cumulative Contribution | -33.79% |
Market Drivers
12/28/2024 to 12/28/2025| Return | Correlation | |
|---|---|---|
| QDEL | -33.8% | |
| Market (SPY) | 17.0% | 43.0% |
| Sector (XLV) | 13.8% | 43.8% |
Fundamental Drivers
The -65.6% change in QDEL stock from 12/29/2022 to 12/28/2025 was primarily driven by a -60.9% change in the company's P/S Multiple.| 12292022 | 12282025 | Change | |
|---|---|---|---|
| Stock Price ($) | 85.14 | 29.30 | -65.59% |
| Change Contribution By | LTM | LTM | |
| Total Revenues ($ Mil) | 3036.40 | 2714.40 | -10.60% |
| P/S Multiple | 1.88 | 0.73 | -60.87% |
| Shares Outstanding (Mil) | 66.90 | 68.00 | -1.64% |
| Cumulative Contribution | -65.60% |
Market Drivers
12/29/2023 to 12/28/2025| Return | Correlation | |
|---|---|---|
| QDEL | -60.2% | |
| Market (SPY) | 48.4% | 32.5% |
| Sector (XLV) | 17.8% | 36.0% |
Price Returns Compared
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| QDEL Return | 139% | -25% | -37% | -14% | -40% | -35% | -61% |
| Peers Return | 16% | 38% | -12% | 21% | 26% | 16% | 150% |
| S&P 500 Return | 16% | 27% | -19% | 24% | 23% | 18% | 114% |
Monthly Win Rates [3] | |||||||
| QDEL Win Rate | 75% | 50% | 42% | 50% | 58% | 42% | |
| Peers Win Rate | 52% | 65% | 42% | 68% | 57% | 52% | |
| S&P 500 Win Rate | 58% | 75% | 42% | 67% | 75% | 73% | |
Max Drawdowns [4] | |||||||
| QDEL Max Drawdown | -3% | -42% | -50% | -32% | -59% | -56% | |
| Peers Max Drawdown | -34% | -5% | -26% | -7% | -9% | -23% | |
| S&P 500 Max Drawdown | -31% | -1% | -25% | -1% | -2% | -15% | |
[1] Cumulative total returns since the beginning of 2020
[2] Peers: HPQ, HPE, IBM, CSCO, AAPL. See QDEL Returns vs. Peers.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2025 data is for the year up to 12/26/2025 (YTD)
How Low Can It Go
| Event | QDEL | S&P 500 |
|---|---|---|
| 2022 Inflation Shock | ||
| % Loss | -77.1% | -25.4% |
| % Gain to Breakeven | 336.7% | 34.1% |
| Time to Breakeven | Not Fully Recovered days | 464 days |
| 2020 Covid Pandemic | ||
| % Loss | -49.7% | -33.9% |
| % Gain to Breakeven | 98.7% | 51.3% |
| Time to Breakeven | Not Fully Recovered days | 148 days |
| 2018 Correction | ||
| % Loss | -42.1% | -19.8% |
| % Gain to Breakeven | 72.6% | 24.7% |
| Time to Breakeven | 380 days | 120 days |
| 2008 Global Financial Crisis | ||
| % Loss | -62.0% | -56.8% |
| % Gain to Breakeven | 163.1% | 131.3% |
| Time to Breakeven | 1,390 days | 1,480 days |
Compare to HPQ, HPE, IBM, CSCO, AAPL
In The Past
QuidelOrtho's stock fell -77.1% during the 2022 Inflation Shock from a high on 2/1/2021. A -77.1% loss requires a 336.7% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth over time.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
Quidel Corporation develops, manufactures, and markets diagnostic testing solutions for applications in infectious diseases, cardiology, thyroid, women's and general health, eye health, gastrointestinal diseases, and toxicology worldwide. It offers Sofia and Sofia 2 fluorescent immunoassay systems; QuickVue, a lateral flow immunoassay products; and InflammaDry and AdenoPlus, a POC products to detect infectious and inflammatory diseases and conditions of the eye. The company also provides Triage MeterPro, a portable testing platform that enables physicians to promote enhanced health outcomes, as well as the detection of certain drugs of abuse; Triage BNP test for use on Beckman Coulter lab analyzers; and Triage TOX drug screen, which provides results for the presence of drug and/or the major metabolites in urine. In addition, it offers traditional cell lines, specimen collection devices, media, and controls for use in laboratories that culture and test for various human viruses, including respiratory and herpes family viruses; and cell-based products comprising tubes, shell vials, and multi-well plates. Further, the company provides biomarkers, which include clinical and research products for the assessment of osteoporosis and the evaluation of bone resorption/formation; and enzyme linked immunosorbent assays and reagents for the detection of activation products. Additionally, it offers Lyra molecular real-time polymerase chain reaction assays; Solana, an amplification and detection system; Savanna, an automated in vitro molecular diagnostic platform; and Virena, a wireless cellular data management and surveillance system. The company markets its products through distributors and direct sales force for use in physician offices, hospitals, clinical laboratories, reference laboratories, universities, retail and urgent care clinics, pharmacies, and wellness screening centers. Quidel Corporation was incorporated in 1979 and is headquartered in San Diego, California.
AI Analysis | Feedback
Like the diagnostics divisions of Abbott Laboratories or Roche.
Similar to the diagnostic testing and instrument business of Becton Dickinson (BD).
AI Analysis | Feedback
- Clinical Laboratory Immunoassay & Chemistry Systems: Provides automated instruments and a broad menu of reagents for high-volume clinical laboratories, covering immunoassay and clinical chemistry diagnostics.
- Rapid Point-of-Care & Over-the-Counter Diagnostic Tests: Offers quick, accessible tests for infectious diseases like COVID-19, influenza, RSV, and strep, designed for immediate results in various settings.
- Transfusion Medicine Solutions: Supplies diagnostic systems and reagents for blood typing, donor screening, and cross-matching to ensure the safety and compatibility of blood transfusions.
- Molecular Diagnostics: Develops and manufactures systems and assays for the detection and quantification of nucleic acids, primarily used for infectious disease testing and pathogen identification.
AI Analysis | Feedback
QuidelOrtho (QDEL) primarily sells its diagnostic products and solutions to other companies and institutions within the healthcare sector, rather than directly to individual consumers.
Based on its public filings, QuidelOrtho does not identify any single named major customer (i.e., no customer accounts for 10% or more of its consolidated net revenues). This indicates a diversified customer base across the healthcare industry.
Its major customers, categorized by type of institution, include:
- Hospitals and Hospital Systems
- Clinical and Reference Laboratories
- Physician Offices and Clinics
- Healthcare Distributors
As these are categories of institutions rather than specific named public companies that meet a major customer threshold, no individual company symbols are applicable.
AI Analysis | Feedback
nullAI Analysis | Feedback
Brian J. Blaser, President and Chief Executive Officer
Mr. Blaser brings over 25 years of senior leadership experience in the in vitro diagnostics industry. Prior to joining QuidelOrtho, he spent 15 years at Abbott Laboratories, where he oversaw the company's diagnostics business, which included core laboratory, point-of-care, rapid, and molecular diagnostics. He also held key leadership roles in operations, finance, and engineering at companies such as Johnson & Johnson, Eastman Kodak, and General Motors. Mr. Blaser currently serves on the Board of Directors for the Advanced Medical Technology Association (AdvaMed), is a member of the Board of Trustees at the University of Dayton, and is a former board member of Quanterix and Meridian Bioscience. He took on the role of President and CEO of QuidelOrtho in May 2024, coming out of retirement.
Joseph M. Busky, Chief Financial Officer
Mr. Busky has over 30 years of experience in corporate finance roles for large, global companies across the diagnostics, medical devices, telecom, and marketing services industries. He has worked for both publicly owned companies and within private equity-owned settings. Before joining Ortho Clinical Diagnostics in July 2020, which later merged to form QuidelOrtho, Mr. Busky served as Chief Financial Officer for Vyaire Medical, Inc. His prior experience also includes serving as CFO of FDH Velocitel, CFO of InnerWorkings, Inc. for seven years, and holding corporate and divisional finance roles for 11 years at Siemens Medical Solutions Diagnostics/Dade Behring Holdings, Inc., Bayer Diagnostics, and Diagnostic Products Corporation, including Chief Accounting Officer at Dade Behring.
Phil McLellan, Chief Operations Officer
Mr. McLellan has led transformative efforts to expand QuidelOrtho's operational scope and capabilities. Prior to his current role, he spent 11 years at Thermo Fisher Scientific, where he led division operations teams for laboratory consumables, genetic analysis, and bioproduction businesses. He also held multiple global manufacturing roles over 12 years with Toyota Motor Manufacturing, where he developed expertise in lean manufacturing and process improvement.
Jonathan Siegrist, PhD, Executive VP of Research & Development and CTO
Dr. Siegrist is responsible for defining and executing the strategic vision for QuidelOrtho's molecular and point-of-care diagnostics portfolios. He leads the management of all functions of the business unit in all regions and is accountable for growing revenue and market share worldwide. Dr. Siegrist joined Quidel in 2010.
Lee Bowman, Chief Human Resources Officer
Mr. Bowman oversees all aspects of people, culture, and human resources strategy at QuidelOrtho. He previously served as Senior Vice President and Chief People Officer at RadNet, where he led initiatives in workforce engagement, diversity and inclusion, and leadership development. His expertise was further developed through significant roles at Edwards Lifesciences, Levi Strauss & Co., and Target.
AI Analysis | Feedback
QuidelOrtho (QDEL) faces several key risks to its business, with the most significant stemming from revenue pressures and integration challenges. The most prominent risk to QuidelOrtho's business is the **significant revenue pressure resulting from declining COVID-19 testing demand and product development failures**. The company has experienced a sharp decline in revenue due to reduced demand for COVID-19 tests and issues with excess inventory in the supply chain. This has been compounded by setbacks in its product pipeline, notably the withdrawal of the FDA 510(k) submission for the Savanna Respiratory Viral Panel-4 test, which was anticipated to be a key growth driver. These factors have directly led to substantial net losses and revised, lower revenue forecasts. Secondly, QuidelOrtho faces considerable **integration challenges and costs associated with its merger with Ortho Clinical Diagnostics**. The company continues to incur costs related to the integration of the two businesses and runs the risk of not fully realizing the anticipated synergies and benefits from the combination. Such integration complexities can impact operational efficiency and financial performance. Finally, the company operates within a **complex and evolving regulatory environment**, which presents ongoing risks. QuidelOrtho must comply with a myriad of healthcare laws and regulations across various jurisdictions. The potential loss of FDA emergency use authorizations for certain products, or difficulties in obtaining traditional regulatory clearances for new diagnostic solutions, could materially and adversely affect its business operations and product offerings.AI Analysis | Feedback
The clear emerging threat to QuidelOrtho is the increasing development and market penetration of highly accurate, rapid, and often multiplexed molecular and immunoassay diagnostic platforms designed for decentralized, point-of-care, or even at-home use. These technologies, often leveraging advances in CRISPR, microfluidics, or advanced isothermal amplification, are capable of performing complex diagnostic analyses closer to the patient, thereby potentially challenging the traditional centralized laboratory model and some of QuidelOrtho's established point-of-care offerings by offering superior speed, expanded multiplexing capability, or greater ease of use outside of traditional lab environments.
AI Analysis | Feedback
QuidelOrtho (NASDAQ: QDEL) operates within the global in vitro diagnostics (IVD) industry, which represented a total addressable market of $48 billion in 2021, excluding COVID-19 related revenue. This market is characterized by a 5-7% steady-state growth rate. QuidelOrtho's diverse portfolio of diagnostic solutions addresses various segments within this market, including immunoassay, molecular testing, clinical chemistry, and transfusion medicine. Key product platforms include Sofia® for rapid lateral-flow tests, Lyra® Assays for real-time PCR, VITROS® Systems for clinical chemistry and immunodiagnostics, and the Savanna® Platform for molecular diagnostics. While the company's 2022 Investor Day Presentation indicates a comprehensive view of the "$48B Total Addressable Market", more granular, specific addressable market sizes for each of QuidelOrtho's individual main products or services are not readily available in the provided search results.AI Analysis | Feedback
QuidelOrtho (QDEL) is expected to drive future revenue growth over the next 2-3 years through several key initiatives and market trends, primarily focusing on its core diagnostic business and global expansion:
- Growth in Core Diagnostic Platforms: The company anticipates continued growth from its core labs, immunohematology, and point-of-care segments. This includes stable renewal rates for its VITROS immunoassay platform and sustained demand for automated testing solutions, particularly from blood banks and hospitals. This growth specifically excludes COVID-19 and U.S. Donor Screening revenue impacts.
- Launch and Expansion of New Diagnostic Products: QuidelOrtho is focused on launching innovative new products to enhance its portfolio. Recent examples include the FDA clearance of its high-sensitivity troponin assay for the VITROS platform, aimed at elevating cardiac testing capabilities, and the QUICKVUE Influenza + SARS Test. These new products are expected to drive long-term differentiation and recurring revenue streams.
- Geographic Expansion and Increased International Penetration: The company is experiencing strong revenue growth in international markets, including EMEA (Europe, Middle East, and Africa), Latin America, Japan, and Asia-Pacific. QuidelOrtho sees significant opportunities for expansion in underpenetrated regions like China, particularly in clinical chemistry and immunoassays, where its differentiated technology is highly valued.
- Adoption of Integrated and Automated Laboratory Solutions: QuidelOrtho is benefiting from an expanding installed base of integrated and automated lab systems. The company's commercial strategy emphasizes leading with integrated analyzers and automation, which drives consistent demand and recurring revenue from associated assays, reagents, and consumables.
AI Analysis | Feedback
Share Repurchases
- QuidelOrtho's board of directors authorized the repurchase of up to $300 million of the company's common stock over two years.
- For the fiscal year ended December 31, 2023, the company completed $7 million in share repurchases.
Share Issuance
- As part of the acquisition of Ortho Clinical Diagnostics by Quidel (which then merged into QuidelOrtho) in the first half of fiscal year 2022, Ortho shareholders received newly issued shares in the combined company, ultimately owning approximately 38%. This transaction had a total consideration of approximately $6.0 billion.
- For the trailing twelve months ended September 2025, QuidelOrtho reported $3 million in issuance of stock.
Outbound Investments
- Quidel (prior to the QuidelOrtho merger) acquired Ortho Clinical Diagnostics for approximately $6.0 billion in a transaction that closed in the first half of fiscal year 2022.
- In December 2023, QuidelOrtho invested in LEX Diagnostics, with the intent to acquire full ownership for approximately $100 million upon FDA clearance, which is anticipated in late 2025 or early 2026.
Capital Expenditures
- Capital expenditures totaled $191.4 million for the fiscal year ended December 31, 2023.
- Capital expenditures amounted to $195 million for the fiscal year ended December 31, 2024.
- The company prioritizes investments in research and development (R&D) and manufacturing capacity expansion, with expected expenditures focused on these areas and manufacturing facility expansions.
Latest Trefis Analyses
| Title | |
|---|---|
| ARTICLES |
Trade Ideas
Select ideas related to QDEL. For more, see Trefis Trade Ideas.
| Date | Ticker | Company | Category | Trade Strategy | 6M Fwd Rtn | 12M Fwd Rtn | 12M Max DD |
|---|---|---|---|---|---|---|---|
| 11142025 | CRL | Charles River Laboratories International | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 21.4% | 21.4% | -3.7% |
| 11142025 | GDRX | GoodRx | Dip Buy | DB | CFO/Rev | Low D/EDip Buy with High Cash Flow MarginsBuying dips for companies with significant cash flows from operations and reasonable debt / market cap | -7.4% | -7.4% | -11.8% |
| 11142025 | ASTH | Astrana Health | Dip Buy | DB | FCF Yield | Low D/EDip Buy with High Free Cash Flow YieldBuying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap | 18.0% | 18.0% | -5.5% |
| 11142025 | SGRY | Surgery Partners | Dip Buy | DB | FCF Yield | Low D/EDip Buy with High Free Cash Flow YieldBuying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap | 3.9% | 3.9% | -1.4% |
| 11072025 | TFX | Teleflex | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 12.2% | 12.2% | -5.1% |
| 09302022 | QDEL | QuidelOrtho | Dip Buy | DB | CFO/Rev | Low D/EDip Buy with High Cash Flow MarginsBuying dips for companies with significant cash flows from operations and reasonable debt / market cap | 24.6% | 2.2% | -5.6% |
| 01312022 | QDEL | QuidelOrtho | Dip Buy | DB | CFO/Rev | Low D/EDip Buy with High Cash Flow MarginsBuying dips for companies with significant cash flows from operations and reasonable debt / market cap | -1.4% | -17.2% | -34.7% |
| 12312020 | QDEL | QuidelOrtho | Dip Buy | DB | P/E OPMDip Buy with Low PE and High MarginBuying dips for companies with tame PE and meaningfully high operating margin | -28.4% | -24.9% | -42.1% |
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons for QuidelOrtho
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 53.73 |
| Mkt Cap | 158.8 |
| Rev LTM | 56,496 |
| Op Inc LTM | 7,584 |
| FCF LTM | 7,327 |
| FCF 3Y Avg | 7,366 |
| CFO LTM | 8,590 |
| CFO 3Y Avg | 8,697 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | 5.2% |
| Rev Chg 3Y Avg | 2.2% |
| Rev Chg Q | 8.3% |
| QoQ Delta Rev Chg LTM | 2.0% |
| Op Mgn LTM | 12.1% |
| Op Mgn 3Y Avg | 11.9% |
| QoQ Delta Op Mgn LTM | -0.1% |
| CFO/Rev LTM | 14.6% |
| CFO/Rev 3Y Avg | 17.1% |
| FCF/Rev LTM | 11.6% |
| FCF/Rev 3Y Avg | 12.1% |
Valuation
| Median | |
|---|---|
| Name | |
| Mkt Cap | 158.8 |
| P/S | 2.7 |
| P/EBIT | 21.2 |
| P/E | 33.0 |
| P/CFO | 21.8 |
| Total Yield | 3.9% |
| Dividend Yield | 2.1% |
| FCF Yield 3Y Avg | 5.7% |
| D/E | 0.4 |
| Net D/E | 0.3 |
Returns
| Median | |
|---|---|
| Name | |
| 1M Rtn | 0.2% |
| 3M Rtn | 5.3% |
| 6M Rtn | 10.9% |
| 12M Rtn | 11.8% |
| 3Y Rtn | 73.5% |
| 1M Excs Rtn | -1.1% |
| 3M Excs Rtn | 1.0% |
| 6M Excs Rtn | -1.3% |
| 12M Excs Rtn | -4.6% |
| 3Y Excs Rtn | -6.2% |
Comparison Analyses
Segment Financials
Revenue by Segment| $ Mil | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Labs | 1,425 | 820 | 45 | ||
| Point of Care | 892 | 1,955 | 1,453 | ||
| Immunohematology | 512 | ||||
| Donor Screening | 136 | ||||
| Molecular Diagnostics | 32 | 97 | 200 | 223 | 22 |
| Transfusion Medicine | 394 | ||||
| Cardiometabolic Immunoassay | 243 | 267 | |||
| Rapid Immunoassay | 1,145 | 192 | |||
| Specialized Diagnostic Solutions | 51 | 55 | |||
| Total | 2,998 | 3,266 | 1,699 | 1,662 | 535 |
Price Behavior
Price Behavior
| Market Price | $29.30 | |
| Market Cap ($ Bil) | 2.0 | |
| First Trading Date | 03/03/1992 | |
| Distance from 52W High | -38.5% | |
| 50 Days | 200 Days | |
| DMA Price | $26.68 | $28.49 |
| DMA Trend | down | down |
| Distance from DMA | 9.8% | 2.8% |
| 3M | 1YR | |
| Volatility | 76.4% | 73.5% |
| Downside Capture | 312.36 | 221.56 |
| Upside Capture | 268.28 | 146.92 |
| Correlation (SPY) | 38.7% | 42.8% |
QDEL Betas & Captures as of 11/30/2025
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
| 1M | 2M | 3M | 6M | 1Y | 3Y | |
|---|---|---|---|---|---|---|
| Beta | 3.35 | 2.41 | 2.54 | 2.50 | 1.59 | 1.21 |
| Up Beta | 2.51 | 1.16 | 1.99 | 2.99 | 1.26 | 1.16 |
| Down Beta | -1.26 | 1.44 | 1.59 | 1.84 | 1.60 | 1.21 |
| Up Capture | 496% | 297% | 299% | 237% | 212% | 61% |
| Bmk +ve Days | 13 | 26 | 39 | 74 | 142 | 427 |
| Stock +ve Days | 10 | 19 | 29 | 55 | 108 | 351 |
| Down Capture | 389% | 311% | 305% | 259% | 147% | 108% |
| Bmk -ve Days | 7 | 16 | 24 | 52 | 107 | 323 |
| Stock -ve Days | 10 | 22 | 33 | 69 | 138 | 393 |
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
| Comparison of QDEL With Other Asset Classes (Last 1Y) | |||||||
|---|---|---|---|---|---|---|---|
| QDEL | Sector ETF | Equity | Gold | Commodities | Real Estate | Bitcoin | |
| Annualized Return | -34.7% | 15.1% | 17.8% | 72.1% | 8.6% | 4.4% | -8.2% |
| Annualized Volatility | 72.8% | 17.2% | 19.4% | 19.3% | 15.2% | 17.0% | 35.0% |
| Sharpe Ratio | -0.30 | 0.65 | 0.72 | 2.70 | 0.34 | 0.09 | -0.08 |
| Correlation With Other Assets | 43.7% | 42.8% | -4.7% | 11.8% | 38.3% | 23.1% | |
ETFs used for asset classes: Sector ETF = XLV, Equity = SPY, Gold = GLD, Commodities = DBC, Real Estate = VNQ, and Bitcoin = BTCUSD
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
| Comparison of QDEL With Other Asset Classes (Last 5Y) | |||||||
|---|---|---|---|---|---|---|---|
| QDEL | Sector ETF | Equity | Gold | Commodities | Real Estate | Bitcoin | |
| Annualized Return | -31.7% | 8.4% | 14.7% | 18.7% | 11.5% | 4.6% | 30.8% |
| Annualized Volatility | 56.7% | 14.5% | 17.1% | 15.5% | 18.7% | 18.9% | 48.6% |
| Sharpe Ratio | -0.44 | 0.40 | 0.70 | 0.97 | 0.50 | 0.16 | 0.57 |
| Correlation With Other Assets | 33.5% | 28.0% | 2.9% | 1.6% | 26.0% | 8.8% | |
ETFs used for asset classes: Sector ETF = XLV, Equity = SPY, Gold = GLD, Commodities = DBC, Real Estate = VNQ, and Bitcoin = BTCUSD
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
| Comparison of QDEL With Other Asset Classes (Last 10Y) | |||||||
|---|---|---|---|---|---|---|---|
| QDEL | Sector ETF | Equity | Gold | Commodities | Real Estate | Bitcoin | |
| Annualized Return | 3.6% | 9.9% | 14.8% | 15.3% | 7.0% | 5.3% | 69.2% |
| Annualized Volatility | 55.1% | 16.6% | 18.0% | 14.7% | 17.6% | 20.8% | 55.8% |
| Sharpe Ratio | 0.29 | 0.49 | 0.71 | 0.86 | 0.32 | 0.22 | 0.90 |
| Correlation With Other Assets | 33.6% | 28.2% | 2.3% | 3.7% | 19.5% | 9.1% | |
ETFs used for asset classes: Sector ETF = XLV, Equity = SPY, Gold = GLD, Commodities = DBC, Real Estate = VNQ, and Bitcoin = BTCUSD
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Returns Analyses
Earnings Returns History
Expand for More| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 11/5/2025 | -22.3% | -17.5% | -0.8% |
| 8/5/2025 | -1.0% | 6.4% | 17.4% |
| 5/7/2025 | 41.0% | 29.8% | 14.2% |
| 2/12/2025 | 4.3% | 2.7% | -9.6% |
| 11/7/2024 | 12.6% | 0.3% | 4.3% |
| 7/31/2024 | 6.9% | 0.8% | 10.9% |
| 5/8/2024 | 2.2% | 5.3% | -2.4% |
| 2/13/2024 | -32.2% | -25.9% | -28.9% |
| ... | |||
| SUMMARY STATS | |||
| # Positive | 7 | 7 | 6 |
| # Negative | 7 | 7 | 8 |
| Median Positive | 5.7% | 2.9% | 12.6% |
| Median Negative | -6.5% | -9.2% | -7.8% |
| Max Positive | 41.0% | 29.8% | 17.4% |
| Max Negative | -32.2% | -25.9% | -28.9% |
SEC Filings
Expand for More| Report Date | Filing Date | Filing |
|---|---|---|
| 09/30/2025 | 11/06/2025 | 10-Q (09/30/2025) |
| 06/30/2025 | 08/06/2025 | 10-Q (06/30/2025) |
| 03/31/2025 | 05/08/2025 | 10-Q (03/31/2025) |
| 12/31/2024 | 02/27/2025 | 10-K (12/31/2024) |
| 09/30/2024 | 11/08/2024 | 10-Q (09/30/2024) |
| 06/30/2024 | 08/01/2024 | 10-Q (06/30/2024) |
| 03/31/2024 | 05/09/2024 | 10-Q (03/31/2024) |
| 12/31/2023 | 02/29/2024 | 10-K (12/31/2023) |
| 09/30/2023 | 11/02/2023 | 10-Q (09/30/2023) |
| 06/30/2023 | 08/09/2023 | 10-Q (06/30/2023) |
| 03/31/2023 | 05/04/2023 | 10-Q (03/31/2023) |
| 12/31/2022 | 02/23/2023 | 10-K (12/31/2022) |
| 09/30/2022 | 11/04/2022 | 10-Q (09/30/2022) |
| 06/30/2022 | 08/05/2022 | 10-Q (06/30/2022) |
| 03/31/2022 | 05/05/2022 | 10-Q (03/31/2022) |
| 12/31/2021 | 02/18/2022 | 10-K (12/31/2021) |
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.